Unresectable Tumour — Surgical Feasibility

The term 'unresectable' describes a surgical boundary rather than the curability of a cancer. A multidisciplinary surgical team classifies a tumour as unresectable when taking it out would cause unacceptable damage to adjacent vital organs or leave behind significant macroscopic disease, offering no therapeutic benefit.

Factors rendering a tumour unresectable include encasement of major blood vessels, extensive infiltration into nearby non-resectable structures, poor general patient health, or distant metastases. In some scenarios, tumours initially deemed unresectable may become resectable after receiving systemic therapy.

Hearing that a tumour cannot be removed surgically can feel distressing, but understanding this classification helps guide discussions toward effective alternative therapies. In many cases, systemic therapy can shrink the tumour—a process known as downstaging—sometimes making surgery possible later. Clarifying this status ensures safe treatment choices tailored to your body.

Resectability is determined using high-resolution imaging such as contrast-enhanced CT, MRI, and PET scans. Surgeons review these scans to measure margins and vascular involvement. Tumour biopsies provide molecular markers (such as KRAS, EGFR, or MSI status) to help select systemic drugs that could shrink the tumour.

This term frequently applies to locally advanced pancreatic cancer, primary liver cancers (hepatocellular carcinoma), advanced non-small cell lung cancer, and head and neck tumours abutting major carotid vessels. It is also common in advanced colorectal cancer with widespread peritoneal or hepatic spread.

Initial management relies on systemic options: chemotherapy, immunotherapy, or targeted therapy. Neoadjuvant therapy aims to shrink the tumour enough to reconsider surgery. Alternatively, definitive chemoradiotherapy or local ablative treatments (like stereotactic radiation or radiofrequency ablation) are used to achieve durable local disease control.